ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846
-A A +A

Patent System and Pharmaceutical Sector

Patent System and Pharmaceutical Sector H Ashok Chandra Prasad Shripad Bhat WHILE we arc not sure of the intention of Biswajit Dhar and C Niranjan Rao('Patent System and Pharmaceutical Sector1, EPW, October 2, 1993) in misinterpreting our analysis twisting our arguments and quoting from different places in the paper ('Strengthening India's Patent System: Implications for Pharmaceutical Sector', EPW, May 22, 1993) without spelling out the context, they do not seem to have been able to come to grips with the ongoing debate on Dunkel draft within the hard realities facing the developing countries and the findings of various research studies on the implications of different patent regimes and the desirability of strengthening patents to promote R and D and the growth of knowledge by protecting the interests of those involved in the process, especially in the context of the enormous costs involved in undertaking certain inventive activities. We do not consider it necessary to answer each of the remarks, academic and unacademic, made by the two critics. However, we wish to place some of the facts and arguments straight, lest the readers be unnecessarily misled by the strange arguments and misinterpretations of Dhar and Rao.

Subscribers please login to access full text of the article.

New 3 Month Subscription
to Digital Archives at

826for India

$50for overseas users

Get instant access to the complete EPW archives

Subscribe now

Comments

(-) Hide

EPW looks forward to your comments. Please note that comments are moderated as per our comments policy. They may take some time to appear. A comment, if suitable, may be selected for publication in the Letters pages of EPW.

Back to Top